TG Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by TG Therapeutics, Inc. on March 17, 2014, reporting events that occurred on March 11, 2014. The filing details the closing of an underwriting agreement for the sale of common stock.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. It specifically discloses the following transaction details and expenses:
- Shares Sold: 2,702,809 shares of Common Stock ($0.001 par value).
- Underwriter: Ladenburg Thalmann & Co. Inc.
- Closing Date: March 17, 2014.
- Transaction Expenses: Total expenses of $50,000.00, allocated as follows:
| Expense Category | Amount |
|---|---|
| Legal Fees and Expenses | $20,000.00 |
| Accountants' Fees and Expenses | $20,000.00 |
| Printing and Duplicating Expenses | $5,000.00 |
| Transfer Agent's Fees and Expenses | $5,000.00 |
| Miscellaneous Expenses | $0 |
| Total | $50,000.00 |
The SEC Registration Fee is noted as previously paid, with no specific amount listed in this text.
Material Changes
The primary material change is the increase in outstanding common stock resulting from the sale of 2,702,809 shares. The filing incorporates an expense table into the Registration Statement (No. 333-189015) on Form S-3.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, future guidance, outlook, or specific risk factors beyond the standard disclosure of the underwriting transaction. No unusual items or contingencies are described in the provided text.
Investor Verification Checklist
- Verify the total proceeds received from the sale of 2,702,809 shares (not explicitly stated in this text).
- Confirm the impact of the new share issuance on existing shareholder dilution.
- Review the full Registration Statement (No. 333-189015) for the use of proceeds and detailed risk factors.
- Check subsequent filings for the actual cash balance impact after the $50,000 in transaction expenses.